S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Is AMC Entertainment Pulling a Fast One on the APEs?
The Five Hottest Calls From The Q2 Earnings Season 
Buffett's firm buys more Apple, Amazon while betting on oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Bargain in Today's Market (SHOCKING) (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Is AMC Entertainment Pulling a Fast One on the APEs?
The Five Hottest Calls From The Q2 Earnings Season 
Buffett's firm buys more Apple, Amazon while betting on oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Bargain in Today's Market (SHOCKING) (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Is AMC Entertainment Pulling a Fast One on the APEs?
The Five Hottest Calls From The Q2 Earnings Season 
Buffett's firm buys more Apple, Amazon while betting on oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Bargain in Today's Market (SHOCKING) (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Is AMC Entertainment Pulling a Fast One on the APEs?
The Five Hottest Calls From The Q2 Earnings Season 
Buffett's firm buys more Apple, Amazon while betting on oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Bargain in Today's Market (SHOCKING) (Ad)pixel
NYSE:CTLT

Catalent - CTLT Stock Forecast, Price & News

$110.85
+0.88 (+0.80%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$108.85
$110.97
50-Day Range
$99.93
$113.71
52-Week Range
$86.34
$142.64
Volume
671,877 shs
Average Volume
1.19 million shs
Market Capitalization
$19.87 billion
P/E Ratio
40.16
Dividend Yield
N/A
Price Target
$142.86

Catalent MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
28.9% Upside
$142.86 Price Target
Short Interest
Healthy
1.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.48mentions of Catalent in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$476,951 Sold Last Quarter
Proj. Earnings Growth
11.76%
From $3.57 to $3.99 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.05 out of 5 stars

Medical Sector

22nd out of 1,125 stocks

Pharmaceutical Preparations Industry

4th out of 554 stocks

CTLT stock logo

About Catalent (NYSE:CTLT) Stock

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Catalent Trading Up 0.8 %

CTLT opened at $110.85 on Tuesday. The firm has a market cap of $19.87 billion, a price-to-earnings ratio of 40.16, a PEG ratio of 1.68 and a beta of 1.29. The company has a current ratio of 2.89, a quick ratio of 2.25 and a debt-to-equity ratio of 0.90. Catalent has a 12 month low of $86.34 and a 12 month high of $142.64. The stock has a fifty day moving average price of $107.64 and a 200-day moving average price of $103.45.

Insider Transactions at Catalent

In other news, CEO Alessandro Maselli sold 816 shares of the business's stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total value of $87,230.40. Following the completion of the transaction, the chief executive officer now directly owns 25,083 shares of the company's stock, valued at approximately $2,681,372.70. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Alessandro Maselli sold 816 shares of the business's stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total transaction of $87,230.40. Following the transaction, the chief executive officer now directly owns 25,083 shares in the company, valued at approximately $2,681,372.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Kay A. Schmidt sold 323 shares of the business's stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total value of $34,528.70. Following the transaction, the senior vice president now owns 13,455 shares in the company, valued at $1,438,339.50. The disclosure for this sale can be found here. In the last three months, insiders sold 4,462 shares of company stock valued at $476,951. Corporate insiders own 0.53% of the company's stock.

Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Stock News Headlines

ASRT vs. CTLT: Which Stock Is the Better Value Option?
See More Headlines
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Company Calendar

Last Earnings
11/01/2021
Today
8/15/2022
Next Earnings (Confirmed)
8/29/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
17,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$142.86
High Stock Price Forecast
$160.00
Low Stock Price Forecast
$110.00
Forecasted Upside/Downside
+28.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$529 million
Pretax Margin
13.10%

Debt

Sales & Book Value

Annual Sales
$4.00 billion
Cash Flow
$4.79 per share
Book Value
$22.98 per share

Miscellaneous

Free Float
178,263,000
Market Cap
$19.87 billion
Optionable
Optionable
Beta
1.29














CTLT Stock - Frequently Asked Questions

Should I buy or sell Catalent stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTLT shares.
View CTLT analyst ratings
or view top-rated stocks.

What is Catalent's stock price forecast for 2022?

7 Wall Street analysts have issued 12 month target prices for Catalent's stock. Their CTLT share price forecasts range from $110.00 to $160.00. On average, they predict the company's stock price to reach $142.86 in the next year. This suggests a possible upside of 28.9% from the stock's current price.
View analysts price targets for CTLT
or view top-rated stocks among Wall Street analysts.

How have CTLT shares performed in 2022?

Catalent's stock was trading at $128.03 at the start of the year. Since then, CTLT shares have decreased by 13.4% and is now trading at $110.85.
View the best growth stocks for 2022 here
.

Are investors shorting Catalent?

Catalent saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 3,130,000 shares, a decline of 20.2% from the July 15th total of 3,920,000 shares. Based on an average trading volume of 1,050,000 shares, the days-to-cover ratio is currently 3.0 days. Currently, 1.9% of the shares of the company are short sold.
View Catalent's Short Interest
.

When is Catalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 29th 2022.
View our CTLT earnings forecast
.

How can I listen to Catalent's earnings call?

Catalent will be holding an earnings conference call on Monday, August 29th at 8:15 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) announced its earnings results on Monday, November, 1st. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.65 by $0.06. The business earned $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a net margin of 10.72% and a trailing twelve-month return on equity of 15.07%. During the same quarter in the previous year, the business posted $0.33 EPS.
Read the conference call transcript
.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Veritas Asset Management LLP (3.85%), Franklin Resources Inc. (3.17%), Artisan Partners Limited Partnership (2.92%), Northern Trust Corp (1.02%), Allianz Asset Management GmbH (0.97%) and TimesSquare Capital Management LLC (0.72%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Mario Gargiulo, Michael J Grippo, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano and Wetteny Joseph.
View institutional ownership trends
.

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $110.85.

How much money does Catalent make?

Catalent (NYSE:CTLT) has a market capitalization of $19.87 billion and generates $4.00 billion in revenue each year. The company earns $529 million in net income (profit) each year or $2.76 on an earnings per share basis.

How many employees does Catalent have?

The company employs 17,300 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480.

This page (NYSE:CTLT) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.